Utah H.B. 390

2026 General Session

This bipartisan bill authorizes the Huntsman Mental Health Institute at The University of Utah Health to conduct a state-led clinical study on the safety and feasibility of psychedelic-assisted therapy for Veterans with treatment-resistant post-traumatic stress disorder (PTSD).

BILL TEXT

DOWNLOAD

“For Veterans who have exhausted conventional treatment for PTSD, this bill would create a legal pathway for them to access psychedelic-assisted therapy through a clinical study overseen by the Health and Human Services Interim Committee.”

– Anya Ragnhildstveit, Lead Scientific Policy Advisor

Chief Sponsor:
Rep. Jennifer Dailey-Provost (D)
Utah House District 22 | Minority Whip
jdprovost@le.utah.gov

Co-Sponsor:
Sen. Kirk A. Cullimore (R)
Utah House District 19 | Majority Leader
kcullimore@le.utah.gov

Current Status:
Last Action: Enrolled bill sent from House to Governor in the Executive Branch - Governor
Date: 3/16/2026 3:47 PM (MST)

What is this bill?

Developed in consultation with clinicians, researchers, and public stakeholders, Rep. Jennifer Dailey-Provost (D) and Sen. Kirk A. Cullimore (R) introduced Utah House Bill 390 (H.B. 390), the “Veterans PTSD Clinical Research Amendments”, during the 2026 General Session. This bipartisan legislation would allow the Huntsman Mental Health Institute to conduct a state-led clinical study evaluating the safety and feasibility of psychedelic-assisted therapy for Veterans with treatment-resistant post-traumatic stress disorder (PTSD).

It is the first state-led research support for psychedelic medicine, representing a critical step in a broader effort to expand access to breakthrough treatments for this highly vulnerable, at-risk patient population and beyond.

WHY DOES IT MATTER?

Veterans are currently experiencing a mental health crisis: PTSD affects Veterans at significantly higher rates than the general population, often leading to profound disability, family strain, and reduced quality of life; more than 60% of Veterans do not respond to evidence-based PTSD treatment, including medication and psychotherapy; and up to 44 Veterans die by suicide or overdose every day — far more than are killed in military combat. This has left many Veterans over-medicated and sedated, feeling detached, hopeless, and alone.

H.B. 390 recognizes this mental health and suicide epidemic, and the urgent for novel, rapid-acting treatments, creating a legal pathway to improve access to psychedelic-assisted therapies that more and more Veterans are seeking.

What DOES IT DO?

H.B. 390 allows qualified clinicians and researchers at the Huntsman Mental Health Institute to conduct a clinical study on the safety and feasibility of psychedelic-assisted therapy for Veterans with treatment-resistant PTSD.

As defined in the bill, the intervention includes the administration of a psychedelic (MDMA, psilocybin, or 5-MeO-DMT) in a controlled and medically supervised setting, combined with trauma-informed psychotherapy delivered before and after administration by a qualified therapist.

It would not, however, legalize or decriminalize any psychedelic, nor create public access to psychedelic-assisted therapy. Participation would be limited to Veterans in the clinical study.